Anti-VEGF terapija u oftalmologiji (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Anti-VEGF terapija u oftalmologiji" in Serbian language version.

refsWebsite

Global rank Serbian rank

49doi.org

2^nd place

4^th place

39nih.gov

4^th place

8^th place

11worldcat.org

5^th place

12^th place

6archive.org

6^th place

5^th place

5semanticscholar.org

11^th place

23^rd place

1oxfordjournals.org

1,389^th place

438^th place

1cines.fr

low place

1web.archive.org

1^st place

archive.org

Meyer, C. H.; Mennel, S.; Schmidt, J. C.; Kroll, P. (2006). „Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration”. Br J Ophthalmol. 90 (9): 1207—08. PMC 1857397 . PMID 16929069. doi:10.1136/bjo.2006.093732. .
Spitzer, M. S.; Wallenfels-Thilo, B.; Sierra, A.; Yoeruek, E.; Peters, S.; Henke-Fahle, S.; Bartz-Schmidt, K. U.; Szurman, P.; Tuebingen Bevacizumab Study Group (2006). „Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells”. Br J Ophthalmol. 90 (10): 1316—21. PMC 1857456 . PMID 16723358. doi:10.1136/bjo.2006.095190. .
Brown, David M.; Michels, Mark; Kaiser; Heier, Jeffrey S.; Sy, Judy P.; Ianchulev, Tsontcho; Anchor Study, Group (2009). „Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study”. Ophthalmology. 116 (1): 57—65. PMID 19118696. doi:10.1016/j.ophtha.2008.10.018. Пронађени су сувишни параметри: |author3= и |last3= (помоћ)
Heier, J. S.; Brown, D. M.; Chong, V.; Korobelnik, J. F.; Kaiser, P. K.; Nguyen, Q. D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G. D.; Stahl, N.; Vitti, R.; Berliner, A. J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U.; VIEW 1 and VIEW 2 Study Groups (2012). „Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration”. Ophthalmology. 119 (12): 2537—2548. PMID 23084240. doi:10.1016/j.ophtha.2012.09.006.
CATT Research Group; Martin, D. F.; Maguire, M. G.; Ying, G. S.; Grunwald, J. E.; Fine, S. L.; Jaffe, G. J. (2011). „Ranibizumab and bevacizumab for neovascular age-related macular degeneration”. New England Journal of Medicine. 364 (20): 1897—1908. PMC 3157322 . PMID 21526923. doi:10.1056/NEJMoa1102673. .
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin, D. F.; Maguire, M. G.; Fine, S. L.; Ying, G. S.; Jaffe, G. J.; Grunwald, J. E.; Toth, C.; Redford, M.; Ferris Fl, 3rd (2012). „Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results”. Ophthalmology. 119 (7): 1388—1398. PMC 3389193 . PMID 22555112. doi:10.1016/j.ophtha.2012.03.053. .

cines.fr

imgt.cines.fr

IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CZ8&Part=Chain Архивирано на веб-сајту Wayback Machine (7. децембар 2008)

doi.org

Jeganathan, V. S.; Verma, N. (2009). „Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration”. Curr. Opin. Ophthalmol. 20 (3): 223—225. PMID 19367163. doi:10.1097/ICU.0b013e328329b656. (2009).
Kaiser, Peter K. (2006). „Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases”. American Journal of Ophthalmology. 142 (4): 660—668.e1. ISSN 0002-9394. PMID 17011860. doi:10.1016/j.ajo.2006.05.061.
Tolentino, M. (2011). „Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease”. Surv. Ophthalmol. 56 (2): 95—113. PMID 21335144. doi:10.1016/j.survophthal.2010.08.006. (2011).
Daekyu Sun; et al. (2005). „Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents”. Nucleic Acids Research. 33 (18): 6070—6080. PMC 1266068 . PMID 16239639. doi:10.1093/nar/gki917.
Daekyu Sun; et al. (2008). „The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents”. Mol Cancer Ther April. 2008 (7): 880—889. PMC 2367258 . PMID 18413801. doi:10.1158/1535-7163.MCT-07-2119.
Fernando, Himesh; Reszka, Anthony P.; Huppert, Julian; Ladame, Sylvain; Rankin, Sarah; Venkitaraman, Ashok R.; Neidle, Stephen; Balasubramanian, Shankar (2006-05-28). „A Conserved Quadruplex Motif Located in a Transcription Activation Site of the Human c-kit Oncogene”. Biochemistry. 45 (25): 7854—7860. ISSN 0006-2960. PMC 2195898 . PMID 16784237. doi:10.1021/bi0601510.
Holmes K, Roberts OL, Thomas AM, Cross MJ (2007). „Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.”. Cell Signal. 19 (10): 2003—2012. PMID 17658244. doi:10.1016/j.cellsig.2007.05.013.
Stuttfeld, E.; Ballmer-Hofer, K. (2009). „Structure and function of VEGF receptors”. IUBMB Life. 61 (9): 915—22. PMID 19658168. S2CID 10190107. doi:10.1002/iub.234.
Fujita, Nobuyuki; Imai, Jun-Ichi; Suzuki, Toru; Yamada, Masayuki; Ninomiya, Ken; Miyamoto, Kana; Iwasaki, Ryotaro; Morioka, Hideo; Matsumoto, Morio; Chiba, Kazuhiro; Watanabe, Shinya; Suda, Toshio; Toyama, Yoshiaki; Miyamoto, Takeshi (2008). „Vascular endothelial growth factor-A is a survival factor for nucleus pulposus cells in the intervertebral disc”. Biochemical and Biophysical Research Communications. 372 (2): 367—372. PMID 18492486. doi:10.1016/j.bbrc.2008.05.044.
Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. (2007). „Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits”. Retina (Philadelphia, Pa.). 27 (9): 1260—6. PMID 18046235. S2CID 9336230. doi:10.1097/IAE.0b013e318134eecd.
Gaudreault, J.; Fei, D.; Rusit, J.; Suboc, P.; Shiu, V. (2005). „Preclinical pharmacokinetics of Ranibizumab (RhuFabV2) after a single intravitreal administration”. Investigative Ophthalmology & Visual Science. 46 (2): 726—33. PMID 15671306. doi:10.1167/iovs.04-0601.
Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. (2007). „Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits”. Retina (Philadelphia, Pa.). 27 (9): 1260—6. PMID 18046235. S2CID 9336230. doi:10.1097/IAE.0b013e318134eecd.
Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Ezzat, M. K.; Singh, R. J. (2007). „Pharmacokinetics of intravitreal ranibizumab (Lucentis)”. Ophthalmology. 114 (12): 2179—82. PMID 18054637. doi:10.1016/j.ophtha.2007.09.012.
Kourlas, H.; Abrams, P. (2007). „Ranibizumab for the treatment of neovascular age-related macular degeneration: A review”. Clinical Therapeutics. 29 (9): 1850—61. PMID 18035187. doi:10.1016/j.clinthera.2007.09.008.
Knox, Craig; Law, Vivian; Jewison, Timothy; Liu, Philip; Ly, Son; Frolkis, Alex; Pon, Allison; Banco, Kelly; Mak, Christine (2011). „DrugBank 3.0: a comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—1041. ISSN 1362-4962. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—906. ISSN 1362-4962. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Gragoudas, E. S.; Adamis, A. P.; Cunningham Jr, E. T.; Feinsod, M.; Guyer, D. R.; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). „Pegaptanib for neovascular age-related macular degeneration”. New England Journal of Medicine. 351 (27): 2805—16. PMID 15625332. S2CID 10050130. doi:10.1056/NEJMoa042760.
Rosenfeld, Philip J.; Brown, David M.; Heier, Jeffrey S.; Boyer, David S.; Kaiser, Peter K.; Chung, Carol Y.; Kim, Robert Y. (2006-10-05). „Ranibizumab for Neovascular Age-Related Macular Degeneration”. New England Journal of Medicine. 355 (14): 1419—1431. ISSN 0028-4793. PMID 17021318. doi:10.1056/nejmoa054481.
Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, J. S.; Kim, R. Y.; Sy, J. P.; Schneider, S.; ANCHOR Study Group (2006). „Ranibizumab versus verteporfin for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1432—44. PMID 17021319. doi:10.1056/NEJMoa062655.
Rosenfeld, Philip J. (2006). „Intravitreal Avastin: The Low Cost Alternative to Lucentis?”. American Journal of Ophthalmology. 142 (1): 141—143. ISSN 0002-9394. PMID 16815262. doi:10.1016/j.ajo.2006.03.036.
Stone, E. M. (2006). „A very effective treatment for neovascular macular degeneration”. New England Journal of Medicine. 355 (14): 1493—95. PMID 17021326. doi:10.1056/NEJMe068191. .
Rich R.M., Rosenfeld P.J., Puliafito C.A. et al.: Short-time safetyand efficacy of intravitreal bevacizumab (Avastin) forneovascular age-realted macular degeneration. Rich, R. M.; Rosenfeld, P. J.; Puliafito, C. A.; Dubovy, S. R.; Davis, J. L.; Flynn Jr, H. W.; Gonzalez, S.; Feuer, W. J.; Lin, R. C.; Lalwani, G. A.; Nguyen, J. K.; Kumar, G. (2006). „Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration”. Retina. 26 (5): 495—511. PMID 16770255. doi:10.1097/01.iae.0000225766.75009.3a. .(abstract)
Avery, Robert L.; Pieramici, Dante J.; Rabena, Melvin D.; Castellarin, Alessandro A.; Nasir, Ma’an A.; Giust, Matthew J. (2006). „Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration”. Ophthalmology. 113 (3): 363—372.e5. ISSN 0161-6420. PMID 16458968. doi:10.1016/j.ophtha.2005.11.019.
Bashshur, Ziad F.; Bazarbachi, Ali; Schakal, Alexandre; Haddad, Zeina A.; El Haibi, Christelle P.; Noureddin, Baha’ N. (2006). „Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration”. American Journal of Ophthalmology. 142 (1): 1—9. ISSN 0002-9394. PMID 16815245. doi:10.1016/j.ajo.2006.02.037.
Meyer, C. H.; Mennel, S.; Schmidt, J. C.; Kroll, P. (2006). „Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration”. Br J Ophthalmol. 90 (9): 1207—08. PMC 1857397 . PMID 16929069. doi:10.1136/bjo.2006.093732. .
Rudd, P; Siegler, M; Byyny, R L (1978). „Perioperative diabetic consultation”. Academic Medicine. 53 (7): 590—6. ISSN 1040-2446. doi:10.1097/00001888-197807000-00007.
Luthra, S.; Narayanan, R.; Marques, L. E.; Chwa, M.; Kim, D. W.; Dong, J.; Seigel, G. M.; Neekhra, A.; Gramajo, A. L.; Brown, D. J.; Kenney, M. C.; Kuppermann, B. D. (2006). „Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells”. Retina. 26 (5): 512—18. PMID 16770256. S2CID 20956318. doi:10.1097/01.iae.0000222547.35820.52. .
Spitzer, M. S.; Wallenfels-Thilo, B.; Sierra, A.; Yoeruek, E.; Peters, S.; Henke-Fahle, S.; Bartz-Schmidt, K. U.; Szurman, P.; Tuebingen Bevacizumab Study Group (2006). „Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells”. Br J Ophthalmol. 90 (10): 1316—21. PMC 1857456 . PMID 16723358. doi:10.1136/bjo.2006.095190. .
MANZANO, ROBERTA P. A.; PEYMAN, GHOLAM A.; KHAN, PALWASHA; KIVILCIM, MUHAMET (2006). „Testing Intravitreal Toxicity of Bevacizumab (Avastin)”. Retina. 26 (3): 257—261. ISSN 0275-004X. PMID 16508423. doi:10.1097/00006982-200603000-00001.
Bakri S.J., Cameron J.D., McCannel C.A. et al.: Abscence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Bakri, S. J.; Cameron, J. D.; McCannel, C. A.; Pulido, J. S.; Marler, R. J. (2006). „Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model”. American Journal of Ophthalmlogy. 142 (1): 162—64. PMID 16815270. doi:10.1016/j.ajo.2006.03.058. .
Grisanti S., Biester S., Peters S. et al.: Intracameral Bevacizumabfor iris rubeosis. Grisanti, S.; Biester, S.; Peters, S.; Tatar, O.; Ziemssen, F.; Bartz-Schmidt, K. U.; Tuebingen Bevacizumab Study Group (2006). „Intracameral bevacizumab for iris rubeosis”. American Journal of Ophthalmology. 142 (1): 158—60. PMID 16815268. doi:10.1016/j.ajo.2006.02.045. .
DAVIDORF, FREDERICK H.; MOUSER, J GARRET; DERICK, ROBERT J. (2006). „Rapid Improvement of Rubeosis Iridis from a Single Bevacizumab (Avastin) Injection”. Retina. 26 (3): 354—356. ISSN 0275-004X. PMID 16508439. doi:10.1097/00006982-200603000-00017.
Brown, David M.; Michels, Mark; Kaiser; Heier, Jeffrey S.; Sy, Judy P.; Ianchulev, Tsontcho; Anchor Study, Group (2009). „Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study”. Ophthalmology. 116 (1): 57—65. PMID 19118696. doi:10.1016/j.ophtha.2008.10.018. Пронађени су сувишни параметри: |author3= и |last3= (помоћ)
Los, M.; Roodhart, J. M.; Voest, E. E. (април 2007). „Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer”. The Oncologist. 12 (4): 443—50. PMID 17470687. doi:10.1634/theoncologist.12-4-443.
Rosenfeld, P. J.; Brown, D. M.; Heier, J. S.; Boyer, D. S.; Kaiser, P. K.; Chung, C. Y.; Kim, R. Y.; MARINA Study Group (2006). „Ranibizumab for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1419—1431. PMID 17021318. doi:10.1056/NEJMoa054481. .
Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, J. S.; Kim, R. Y.; Sy, J. P.; Schneider, S.; ANCHOR Study Group (2006). „Ranibizumab versus verteporfin for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1432—1444. PMID 17021319. doi:10.1056/NEJMoa062655. .
Heier, J. S.; Brown, D. M.; Chong, V.; Korobelnik, J. F.; Kaiser, P. K.; Nguyen, Q. D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G. D.; Stahl, N.; Vitti, R.; Berliner, A. J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U.; VIEW 1 and VIEW 2 Study Groups (2012). „Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration”. Ophthalmology. 119 (12): 2537—2548. PMID 23084240. doi:10.1016/j.ophtha.2012.09.006.
CATT Research Group; Martin, D. F.; Maguire, M. G.; Ying, G. S.; Grunwald, J. E.; Fine, S. L.; Jaffe, G. J. (2011). „Ranibizumab and bevacizumab for neovascular age-related macular degeneration”. New England Journal of Medicine. 364 (20): 1897—1908. PMC 3157322 . PMID 21526923. doi:10.1056/NEJMoa1102673. .
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin, D. F.; Maguire, M. G.; Fine, S. L.; Ying, G. S.; Jaffe, G. J.; Grunwald, J. E.; Toth, C.; Redford, M.; Ferris Fl, 3rd (2012). „Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results”. Ophthalmology. 119 (7): 1388—1398. PMC 3389193 . PMID 22555112. doi:10.1016/j.ophtha.2012.03.053. .
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Maguire, M. G.; Martin, D. F.; Ying, G. S.; Jaffe, G. J.; Daniel, E.; Grunwald, J. E.; Toth, C. A.; Ferris Fl, 3rd; Fine, S. L. (2016). „Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials”. Ophthalmology. 123 (8): 1751—1761. PMC 4958614 . PMID 27156698. doi:10.1016/j.ophtha.2016.03.045. .

dx.doi.org

Kaiser, Peter K. (2006). „Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases”. American Journal of Ophthalmology. 142 (4): 660—668.e1. ISSN 0002-9394. PMID 17011860. doi:10.1016/j.ajo.2006.05.061.
Fernando, Himesh; Reszka, Anthony P.; Huppert, Julian; Ladame, Sylvain; Rankin, Sarah; Venkitaraman, Ashok R.; Neidle, Stephen; Balasubramanian, Shankar (2006-05-28). „A Conserved Quadruplex Motif Located in a Transcription Activation Site of the Human c-kit Oncogene”. Biochemistry. 45 (25): 7854—7860. ISSN 0006-2960. PMC 2195898 . PMID 16784237. doi:10.1021/bi0601510.
Rosenfeld, Philip J.; Brown, David M.; Heier, Jeffrey S.; Boyer, David S.; Kaiser, Peter K.; Chung, Carol Y.; Kim, Robert Y. (2006-10-05). „Ranibizumab for Neovascular Age-Related Macular Degeneration”. New England Journal of Medicine. 355 (14): 1419—1431. ISSN 0028-4793. PMID 17021318. doi:10.1056/nejmoa054481.
Rosenfeld, Philip J. (2006). „Intravitreal Avastin: The Low Cost Alternative to Lucentis?”. American Journal of Ophthalmology. 142 (1): 141—143. ISSN 0002-9394. PMID 16815262. doi:10.1016/j.ajo.2006.03.036.
Avery, Robert L.; Pieramici, Dante J.; Rabena, Melvin D.; Castellarin, Alessandro A.; Nasir, Ma’an A.; Giust, Matthew J. (2006). „Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration”. Ophthalmology. 113 (3): 363—372.e5. ISSN 0161-6420. PMID 16458968. doi:10.1016/j.ophtha.2005.11.019.
Bashshur, Ziad F.; Bazarbachi, Ali; Schakal, Alexandre; Haddad, Zeina A.; El Haibi, Christelle P.; Noureddin, Baha’ N. (2006). „Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration”. American Journal of Ophthalmology. 142 (1): 1—9. ISSN 0002-9394. PMID 16815245. doi:10.1016/j.ajo.2006.02.037.
Rudd, P; Siegler, M; Byyny, R L (1978). „Perioperative diabetic consultation”. Academic Medicine. 53 (7): 590—6. ISSN 1040-2446. doi:10.1097/00001888-197807000-00007.
MANZANO, ROBERTA P. A.; PEYMAN, GHOLAM A.; KHAN, PALWASHA; KIVILCIM, MUHAMET (2006). „Testing Intravitreal Toxicity of Bevacizumab (Avastin)”. Retina. 26 (3): 257—261. ISSN 0275-004X. PMID 16508423. doi:10.1097/00006982-200603000-00001.
DAVIDORF, FREDERICK H.; MOUSER, J GARRET; DERICK, ROBERT J. (2006). „Rapid Improvement of Rubeosis Iridis from a Single Bevacizumab (Avastin) Injection”. Retina. 26 (3): 354—356. ISSN 0275-004X. PMID 16508439. doi:10.1097/00006982-200603000-00017.

nih.gov

ncbi.nlm.nih.gov

Jeganathan, V. S.; Verma, N. (2009). „Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration”. Curr. Opin. Ophthalmol. 20 (3): 223—225. PMID 19367163. doi:10.1097/ICU.0b013e328329b656. (2009).
Kaiser, Peter K. (2006). „Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases”. American Journal of Ophthalmology. 142 (4): 660—668.e1. ISSN 0002-9394. PMID 17011860. doi:10.1016/j.ajo.2006.05.061.
Tolentino, M. (2011). „Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease”. Surv. Ophthalmol. 56 (2): 95—113. PMID 21335144. doi:10.1016/j.survophthal.2010.08.006. (2011).
Daekyu Sun; et al. (2005). „Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents”. Nucleic Acids Research. 33 (18): 6070—6080. PMC 1266068 . PMID 16239639. doi:10.1093/nar/gki917.
Daekyu Sun; et al. (2008). „The proximal promoter region of the human vascular endothelial growth factor gene has a G-quadruplex structure that can be targeted by G-quadruplex–interactive agents”. Mol Cancer Ther April. 2008 (7): 880—889. PMC 2367258 . PMID 18413801. doi:10.1158/1535-7163.MCT-07-2119.
Fernando, Himesh; Reszka, Anthony P.; Huppert, Julian; Ladame, Sylvain; Rankin, Sarah; Venkitaraman, Ashok R.; Neidle, Stephen; Balasubramanian, Shankar (2006-05-28). „A Conserved Quadruplex Motif Located in a Transcription Activation Site of the Human c-kit Oncogene”. Biochemistry. 45 (25): 7854—7860. ISSN 0006-2960. PMC 2195898 . PMID 16784237. doi:10.1021/bi0601510.
Holmes K, Roberts OL, Thomas AM, Cross MJ (2007). „Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.”. Cell Signal. 19 (10): 2003—2012. PMID 17658244. doi:10.1016/j.cellsig.2007.05.013.
Stuttfeld, E.; Ballmer-Hofer, K. (2009). „Structure and function of VEGF receptors”. IUBMB Life. 61 (9): 915—22. PMID 19658168. S2CID 10190107. doi:10.1002/iub.234.
Fujita, Nobuyuki; Imai, Jun-Ichi; Suzuki, Toru; Yamada, Masayuki; Ninomiya, Ken; Miyamoto, Kana; Iwasaki, Ryotaro; Morioka, Hideo; Matsumoto, Morio; Chiba, Kazuhiro; Watanabe, Shinya; Suda, Toshio; Toyama, Yoshiaki; Miyamoto, Takeshi (2008). „Vascular endothelial growth factor-A is a survival factor for nucleus pulposus cells in the intervertebral disc”. Biochemical and Biophysical Research Communications. 372 (2): 367—372. PMID 18492486. doi:10.1016/j.bbrc.2008.05.044.
Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. (2007). „Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits”. Retina (Philadelphia, Pa.). 27 (9): 1260—6. PMID 18046235. S2CID 9336230. doi:10.1097/IAE.0b013e318134eecd.
Gaudreault, J.; Fei, D.; Rusit, J.; Suboc, P.; Shiu, V. (2005). „Preclinical pharmacokinetics of Ranibizumab (RhuFabV2) after a single intravitreal administration”. Investigative Ophthalmology & Visual Science. 46 (2): 726—33. PMID 15671306. doi:10.1167/iovs.04-0601.
Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. (2007). „Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits”. Retina (Philadelphia, Pa.). 27 (9): 1260—6. PMID 18046235. S2CID 9336230. doi:10.1097/IAE.0b013e318134eecd.
Bakri, S. J.; Snyder, M. R.; Reid, J. M.; Pulido, J. S.; Ezzat, M. K.; Singh, R. J. (2007). „Pharmacokinetics of intravitreal ranibizumab (Lucentis)”. Ophthalmology. 114 (12): 2179—82. PMID 18054637. doi:10.1016/j.ophtha.2007.09.012.
Kourlas, H.; Abrams, P. (2007). „Ranibizumab for the treatment of neovascular age-related macular degeneration: A review”. Clinical Therapeutics. 29 (9): 1850—61. PMID 18035187. doi:10.1016/j.clinthera.2007.09.008.
Knox, Craig; Law, Vivian; Jewison, Timothy; Liu, Philip; Ly, Son; Frolkis, Alex; Pon, Allison; Banco, Kelly; Mak, Christine (2011). „DrugBank 3.0: a comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—1041. ISSN 1362-4962. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—906. ISSN 1362-4962. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Gragoudas, E. S.; Adamis, A. P.; Cunningham Jr, E. T.; Feinsod, M.; Guyer, D. R.; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). „Pegaptanib for neovascular age-related macular degeneration”. New England Journal of Medicine. 351 (27): 2805—16. PMID 15625332. S2CID 10050130. doi:10.1056/NEJMoa042760.
Rosenfeld, Philip J.; Brown, David M.; Heier, Jeffrey S.; Boyer, David S.; Kaiser, Peter K.; Chung, Carol Y.; Kim, Robert Y. (2006-10-05). „Ranibizumab for Neovascular Age-Related Macular Degeneration”. New England Journal of Medicine. 355 (14): 1419—1431. ISSN 0028-4793. PMID 17021318. doi:10.1056/nejmoa054481.
Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, J. S.; Kim, R. Y.; Sy, J. P.; Schneider, S.; ANCHOR Study Group (2006). „Ranibizumab versus verteporfin for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1432—44. PMID 17021319. doi:10.1056/NEJMoa062655.
Rosenfeld, Philip J. (2006). „Intravitreal Avastin: The Low Cost Alternative to Lucentis?”. American Journal of Ophthalmology. 142 (1): 141—143. ISSN 0002-9394. PMID 16815262. doi:10.1016/j.ajo.2006.03.036.
Stone, E. M. (2006). „A very effective treatment for neovascular macular degeneration”. New England Journal of Medicine. 355 (14): 1493—95. PMID 17021326. doi:10.1056/NEJMe068191. .
Rich R.M., Rosenfeld P.J., Puliafito C.A. et al.: Short-time safetyand efficacy of intravitreal bevacizumab (Avastin) forneovascular age-realted macular degeneration. Rich, R. M.; Rosenfeld, P. J.; Puliafito, C. A.; Dubovy, S. R.; Davis, J. L.; Flynn Jr, H. W.; Gonzalez, S.; Feuer, W. J.; Lin, R. C.; Lalwani, G. A.; Nguyen, J. K.; Kumar, G. (2006). „Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration”. Retina. 26 (5): 495—511. PMID 16770255. doi:10.1097/01.iae.0000225766.75009.3a. .(abstract)
Avery, Robert L.; Pieramici, Dante J.; Rabena, Melvin D.; Castellarin, Alessandro A.; Nasir, Ma’an A.; Giust, Matthew J. (2006). „Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration”. Ophthalmology. 113 (3): 363—372.e5. ISSN 0161-6420. PMID 16458968. doi:10.1016/j.ophtha.2005.11.019.
Bashshur, Ziad F.; Bazarbachi, Ali; Schakal, Alexandre; Haddad, Zeina A.; El Haibi, Christelle P.; Noureddin, Baha’ N. (2006). „Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration”. American Journal of Ophthalmology. 142 (1): 1—9. ISSN 0002-9394. PMID 16815245. doi:10.1016/j.ajo.2006.02.037.
Meyer, C. H.; Mennel, S.; Schmidt, J. C.; Kroll, P. (2006). „Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration”. Br J Ophthalmol. 90 (9): 1207—08. PMC 1857397 . PMID 16929069. doi:10.1136/bjo.2006.093732. .
Luthra, S.; Narayanan, R.; Marques, L. E.; Chwa, M.; Kim, D. W.; Dong, J.; Seigel, G. M.; Neekhra, A.; Gramajo, A. L.; Brown, D. J.; Kenney, M. C.; Kuppermann, B. D. (2006). „Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells”. Retina. 26 (5): 512—18. PMID 16770256. S2CID 20956318. doi:10.1097/01.iae.0000222547.35820.52. .
Spitzer, M. S.; Wallenfels-Thilo, B.; Sierra, A.; Yoeruek, E.; Peters, S.; Henke-Fahle, S.; Bartz-Schmidt, K. U.; Szurman, P.; Tuebingen Bevacizumab Study Group (2006). „Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells”. Br J Ophthalmol. 90 (10): 1316—21. PMC 1857456 . PMID 16723358. doi:10.1136/bjo.2006.095190. .
MANZANO, ROBERTA P. A.; PEYMAN, GHOLAM A.; KHAN, PALWASHA; KIVILCIM, MUHAMET (2006). „Testing Intravitreal Toxicity of Bevacizumab (Avastin)”. Retina. 26 (3): 257—261. ISSN 0275-004X. PMID 16508423. doi:10.1097/00006982-200603000-00001.
Bakri S.J., Cameron J.D., McCannel C.A. et al.: Abscence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Bakri, S. J.; Cameron, J. D.; McCannel, C. A.; Pulido, J. S.; Marler, R. J. (2006). „Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model”. American Journal of Ophthalmlogy. 142 (1): 162—64. PMID 16815270. doi:10.1016/j.ajo.2006.03.058. .
Grisanti S., Biester S., Peters S. et al.: Intracameral Bevacizumabfor iris rubeosis. Grisanti, S.; Biester, S.; Peters, S.; Tatar, O.; Ziemssen, F.; Bartz-Schmidt, K. U.; Tuebingen Bevacizumab Study Group (2006). „Intracameral bevacizumab for iris rubeosis”. American Journal of Ophthalmology. 142 (1): 158—60. PMID 16815268. doi:10.1016/j.ajo.2006.02.045. .
DAVIDORF, FREDERICK H.; MOUSER, J GARRET; DERICK, ROBERT J. (2006). „Rapid Improvement of Rubeosis Iridis from a Single Bevacizumab (Avastin) Injection”. Retina. 26 (3): 354—356. ISSN 0275-004X. PMID 16508439. doi:10.1097/00006982-200603000-00017.
Brown, David M.; Michels, Mark; Kaiser; Heier, Jeffrey S.; Sy, Judy P.; Ianchulev, Tsontcho; Anchor Study, Group (2009). „Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study”. Ophthalmology. 116 (1): 57—65. PMID 19118696. doi:10.1016/j.ophtha.2008.10.018. Пронађени су сувишни параметри: |author3= и |last3= (помоћ)
Los, M.; Roodhart, J. M.; Voest, E. E. (април 2007). „Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer”. The Oncologist. 12 (4): 443—50. PMID 17470687. doi:10.1634/theoncologist.12-4-443.
Rosenfeld, P. J.; Brown, D. M.; Heier, J. S.; Boyer, D. S.; Kaiser, P. K.; Chung, C. Y.; Kim, R. Y.; MARINA Study Group (2006). „Ranibizumab for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1419—1431. PMID 17021318. doi:10.1056/NEJMoa054481. .
Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, J. S.; Kim, R. Y.; Sy, J. P.; Schneider, S.; ANCHOR Study Group (2006). „Ranibizumab versus verteporfin for neovascular age-related macular degeneration”. New England Journal of Medicine. 355 (14): 1432—1444. PMID 17021319. doi:10.1056/NEJMoa062655. .
Heier, J. S.; Brown, D. M.; Chong, V.; Korobelnik, J. F.; Kaiser, P. K.; Nguyen, Q. D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G. D.; Stahl, N.; Vitti, R.; Berliner, A. J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U.; VIEW 1 and VIEW 2 Study Groups (2012). „Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration”. Ophthalmology. 119 (12): 2537—2548. PMID 23084240. doi:10.1016/j.ophtha.2012.09.006.
CATT Research Group; Martin, D. F.; Maguire, M. G.; Ying, G. S.; Grunwald, J. E.; Fine, S. L.; Jaffe, G. J. (2011). „Ranibizumab and bevacizumab for neovascular age-related macular degeneration”. New England Journal of Medicine. 364 (20): 1897—1908. PMC 3157322 . PMID 21526923. doi:10.1056/NEJMoa1102673. .
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Martin, D. F.; Maguire, M. G.; Fine, S. L.; Ying, G. S.; Jaffe, G. J.; Grunwald, J. E.; Toth, C.; Redford, M.; Ferris Fl, 3rd (2012). „Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results”. Ophthalmology. 119 (7): 1388—1398. PMC 3389193 . PMID 22555112. doi:10.1016/j.ophtha.2012.03.053. .
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Maguire, M. G.; Martin, D. F.; Ying, G. S.; Jaffe, G. J.; Daniel, E.; Grunwald, J. E.; Toth, C. A.; Ferris Fl, 3rd; Fine, S. L. (2016). „Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials”. Ophthalmology. 123 (8): 1751—1761. PMC 4958614 . PMID 27156698. doi:10.1016/j.ophtha.2016.03.045. .

oxfordjournals.org

nar.oxfordjournals.org

Daekyu Sun; et al. (2005). „Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents”. Nucleic Acids Research. 33 (18): 6070—6080. PMC 1266068 . PMID 16239639. doi:10.1093/nar/gki917.

semanticscholar.org

api.semanticscholar.org

Stuttfeld, E.; Ballmer-Hofer, K. (2009). „Structure and function of VEGF receptors”. IUBMB Life. 61 (9): 915—22. PMID 19658168. S2CID 10190107. doi:10.1002/iub.234.
Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. (2007). „Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits”. Retina (Philadelphia, Pa.). 27 (9): 1260—6. PMID 18046235. S2CID 9336230. doi:10.1097/IAE.0b013e318134eecd.
Gaudreault, J.; Fei, D.; Beyer, J. C.; Ryan, A.; Rangell, L.; Shiu, V.; Damico, L. A. (2007). „Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits”. Retina (Philadelphia, Pa.). 27 (9): 1260—6. PMID 18046235. S2CID 9336230. doi:10.1097/IAE.0b013e318134eecd.
Gragoudas, E. S.; Adamis, A. P.; Cunningham Jr, E. T.; Feinsod, M.; Guyer, D. R.; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004). „Pegaptanib for neovascular age-related macular degeneration”. New England Journal of Medicine. 351 (27): 2805—16. PMID 15625332. S2CID 10050130. doi:10.1056/NEJMoa042760.
Luthra, S.; Narayanan, R.; Marques, L. E.; Chwa, M.; Kim, D. W.; Dong, J.; Seigel, G. M.; Neekhra, A.; Gramajo, A. L.; Brown, D. J.; Kenney, M. C.; Kuppermann, B. D. (2006). „Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells”. Retina. 26 (5): 512—18. PMID 16770256. S2CID 20956318. doi:10.1097/01.iae.0000222547.35820.52. .

web.archive.org

IGMT Link:http://imgt.cines.fr/3Dstructure-DB/cgi/details.cgi?pdbcode=1CZ8&Part=Chain Архивирано на веб-сајту Wayback Machine (7. децембар 2008)

worldcat.org

Kaiser, Peter K. (2006). „Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases”. American Journal of Ophthalmology. 142 (4): 660—668.e1. ISSN 0002-9394. PMID 17011860. doi:10.1016/j.ajo.2006.05.061.
Fernando, Himesh; Reszka, Anthony P.; Huppert, Julian; Ladame, Sylvain; Rankin, Sarah; Venkitaraman, Ashok R.; Neidle, Stephen; Balasubramanian, Shankar (2006-05-28). „A Conserved Quadruplex Motif Located in a Transcription Activation Site of the Human c-kit Oncogene”. Biochemistry. 45 (25): 7854—7860. ISSN 0006-2960. PMC 2195898 . PMID 16784237. doi:10.1021/bi0601510.
Knox, Craig; Law, Vivian; Jewison, Timothy; Liu, Philip; Ly, Son; Frolkis, Alex; Pon, Allison; Banco, Kelly; Mak, Christine (2011). „DrugBank 3.0: a comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—1041. ISSN 1362-4962. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—906. ISSN 1362-4962. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Rosenfeld, Philip J.; Brown, David M.; Heier, Jeffrey S.; Boyer, David S.; Kaiser, Peter K.; Chung, Carol Y.; Kim, Robert Y. (2006-10-05). „Ranibizumab for Neovascular Age-Related Macular Degeneration”. New England Journal of Medicine. 355 (14): 1419—1431. ISSN 0028-4793. PMID 17021318. doi:10.1056/nejmoa054481.
Rosenfeld, Philip J. (2006). „Intravitreal Avastin: The Low Cost Alternative to Lucentis?”. American Journal of Ophthalmology. 142 (1): 141—143. ISSN 0002-9394. PMID 16815262. doi:10.1016/j.ajo.2006.03.036.
Avery, Robert L.; Pieramici, Dante J.; Rabena, Melvin D.; Castellarin, Alessandro A.; Nasir, Ma’an A.; Giust, Matthew J. (2006). „Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration”. Ophthalmology. 113 (3): 363—372.e5. ISSN 0161-6420. PMID 16458968. doi:10.1016/j.ophtha.2005.11.019.
Bashshur, Ziad F.; Bazarbachi, Ali; Schakal, Alexandre; Haddad, Zeina A.; El Haibi, Christelle P.; Noureddin, Baha’ N. (2006). „Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration”. American Journal of Ophthalmology. 142 (1): 1—9. ISSN 0002-9394. PMID 16815245. doi:10.1016/j.ajo.2006.02.037.
Rudd, P; Siegler, M; Byyny, R L (1978). „Perioperative diabetic consultation”. Academic Medicine. 53 (7): 590—6. ISSN 1040-2446. doi:10.1097/00001888-197807000-00007.
MANZANO, ROBERTA P. A.; PEYMAN, GHOLAM A.; KHAN, PALWASHA; KIVILCIM, MUHAMET (2006). „Testing Intravitreal Toxicity of Bevacizumab (Avastin)”. Retina. 26 (3): 257—261. ISSN 0275-004X. PMID 16508423. doi:10.1097/00006982-200603000-00001.
DAVIDORF, FREDERICK H.; MOUSER, J GARRET; DERICK, ROBERT J. (2006). „Rapid Improvement of Rubeosis Iridis from a Single Bevacizumab (Avastin) Injection”. Retina. 26 (3): 354—356. ISSN 0275-004X. PMID 16508439. doi:10.1097/00006982-200603000-00017.